Case-report: EBV driven lymphoproliferative disorder associated with Ruxolitinib

BACKGROUND: Ruxolitinib, a novel inhibitor of Janus kinases 1 and 2, was recently approved for the treatment of myelofibrosis but, recently, attention has been drawn to potential side effects and especially opportunistic infections and virus reactivations. EBV reactivation has not previously been re...

Descripción completa

Detalles Bibliográficos
Autores principales: Pálmason, Róbert, Lindén, Ola, Richter, Johan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4498562/
https://www.ncbi.nlm.nih.gov/pubmed/26167286
http://dx.doi.org/10.1186/s12878-015-0029-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4498562/
https://www.ncbi.nlm.nih.gov/pubmed/26167286
http://dx.doi.org/10.1186/s12878-015-0029-1

Ejemplares similares